An anti-ER “Riptac” enters phase 1.
ApexOnco Front Page
Recent articles
Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
Bristol renews its focus on chronic lymphocytic leukaemia, but rivals haven’t fared so well here.
Three years after licensing in the IAP inhibitor xevinapant Merck KGaA will find out if the deal was worth it.
Analysis of industry assets newly into human trials reveals three Car-T therapies and some familiar targets.
The first case reports with the group’s lead Car-T therapy, plus talk of autoimmune diseases and diabetes, prompt a 39% share price surge.
Several companies have followed Pfizer into CDK2 inhibitor development, but the jury is out on this field’s promise.
Ambrx’s PSMA-targeting ADC generated puzzling data at ESMO, but J&J has seen enough to launch a premium-priced buyout.